Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
November 03, 2023 12:19 ET
|
Korro Bio, Inc.
Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially...
Korro Bio Announces Appointment of Tim Pearson to Board of Directors Upon Closing of the Proposed Merger and Promotion of Todd Chappell to Chief Operating Officer
October 25, 2023 08:00 ET
|
Korro Bio, Inc.
Tim Pearson, CEO of Carrick Therapeutics and ex-CFO of TESARO, will join as Director contingent on the close of the proposed merger with FrequencyTodd Chappell is elevated to role of Chief Operating...